Expert Opinion: Recent Approval of Cladribine in EU

SPECIAL REPORT: Expert Opinion on New MS Drug Approval

Expert insight into the recent approval of Cladribine for active relapsing multiple sclerosis.
  • Overview

    Professor Ralf Gold offers unique insight into the recent EU approval of Cladribine, a treatment for active relapsing multiple sclerosis. This short discussion reviews the path to approval, the importance of the first approval for an oral short-course treatment option, and the future holds for this drug.

    To learn more about current and future treatment options for MS patients, click here

  • Faculty

    Professor Ralf Gold
    Global Neurology Academy Steering Committee Member
    Professor and Department Chair
    St Josef Spital; Ruhr University Bochum
    Bochum, Germany

Facebook Comments

Sign-up for the Global Neurology Academy newsletters.
Comprehensive Neurology Education.

Better education for a better you.

* Required